Immunotherapy III: Combinatorial molecular immunotherapy - A synthesis and suggestions

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Animal models have clearly shown that tumor cells may be amenable to molecular manipulation which can result in immune activation and rejection of unmodified cells. The challenge now is to design clinical trials which have a realistic chance of success, (although the definition of 'success' is itself an important issue). How should such a strategy be formulated? A review of the previous fifteen years since the first (immune) gene transfer studies were reported, encompasses a great wealth of data. Unfortunately, far from crystallising a set of unifying principles, these diverse reports shroud us in a fog of uncertainty as to how best to proceed. However, if this technology is to have practical, widespread application in the treatment of cancer patients, it is necessary to identify certain critical immunological goals which any protocols should achieve. Clear elucidation of these goals, by unifying the huge amount of disparate experimental data, must eventually be accomplished. In this chapter, we have reviewed the literature covering the era of molecular immunotherapy. We propose four general goals around which widely applicable clinical protocols, not necessarily dependent upon tumour type or experimental bias, might be based and suggest how they may be achieved in the context of gene transfer.

Original languageEnglish (US)
Pages (from-to)351-364
Number of pages14
JournalCancer and Metastasis Reviews
Volume15
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasms
Clinical Protocols
Genes
Uncertainty
Animal Models
Clinical Trials
Technology
Therapeutics

Keywords

  • antigen presentation
  • cytokines
  • gene therapy
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunotherapy III : Combinatorial molecular immunotherapy - A synthesis and suggestions. / Vile, Richard Geoffrey; Chong, Heung.

In: Cancer and Metastasis Reviews, Vol. 15, No. 3, 1996, p. 351-364.

Research output: Contribution to journalArticle

@article{02eda2cf7170491290a7cf6c4f3a7c44,
title = "Immunotherapy III: Combinatorial molecular immunotherapy - A synthesis and suggestions",
abstract = "Animal models have clearly shown that tumor cells may be amenable to molecular manipulation which can result in immune activation and rejection of unmodified cells. The challenge now is to design clinical trials which have a realistic chance of success, (although the definition of 'success' is itself an important issue). How should such a strategy be formulated? A review of the previous fifteen years since the first (immune) gene transfer studies were reported, encompasses a great wealth of data. Unfortunately, far from crystallising a set of unifying principles, these diverse reports shroud us in a fog of uncertainty as to how best to proceed. However, if this technology is to have practical, widespread application in the treatment of cancer patients, it is necessary to identify certain critical immunological goals which any protocols should achieve. Clear elucidation of these goals, by unifying the huge amount of disparate experimental data, must eventually be accomplished. In this chapter, we have reviewed the literature covering the era of molecular immunotherapy. We propose four general goals around which widely applicable clinical protocols, not necessarily dependent upon tumour type or experimental bias, might be based and suggest how they may be achieved in the context of gene transfer.",
keywords = "antigen presentation, cytokines, gene therapy, immunotherapy",
author = "Vile, {Richard Geoffrey} and Heung Chong",
year = "1996",
language = "English (US)",
volume = "15",
pages = "351--364",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Immunotherapy III

T2 - Combinatorial molecular immunotherapy - A synthesis and suggestions

AU - Vile, Richard Geoffrey

AU - Chong, Heung

PY - 1996

Y1 - 1996

N2 - Animal models have clearly shown that tumor cells may be amenable to molecular manipulation which can result in immune activation and rejection of unmodified cells. The challenge now is to design clinical trials which have a realistic chance of success, (although the definition of 'success' is itself an important issue). How should such a strategy be formulated? A review of the previous fifteen years since the first (immune) gene transfer studies were reported, encompasses a great wealth of data. Unfortunately, far from crystallising a set of unifying principles, these diverse reports shroud us in a fog of uncertainty as to how best to proceed. However, if this technology is to have practical, widespread application in the treatment of cancer patients, it is necessary to identify certain critical immunological goals which any protocols should achieve. Clear elucidation of these goals, by unifying the huge amount of disparate experimental data, must eventually be accomplished. In this chapter, we have reviewed the literature covering the era of molecular immunotherapy. We propose four general goals around which widely applicable clinical protocols, not necessarily dependent upon tumour type or experimental bias, might be based and suggest how they may be achieved in the context of gene transfer.

AB - Animal models have clearly shown that tumor cells may be amenable to molecular manipulation which can result in immune activation and rejection of unmodified cells. The challenge now is to design clinical trials which have a realistic chance of success, (although the definition of 'success' is itself an important issue). How should such a strategy be formulated? A review of the previous fifteen years since the first (immune) gene transfer studies were reported, encompasses a great wealth of data. Unfortunately, far from crystallising a set of unifying principles, these diverse reports shroud us in a fog of uncertainty as to how best to proceed. However, if this technology is to have practical, widespread application in the treatment of cancer patients, it is necessary to identify certain critical immunological goals which any protocols should achieve. Clear elucidation of these goals, by unifying the huge amount of disparate experimental data, must eventually be accomplished. In this chapter, we have reviewed the literature covering the era of molecular immunotherapy. We propose four general goals around which widely applicable clinical protocols, not necessarily dependent upon tumour type or experimental bias, might be based and suggest how they may be achieved in the context of gene transfer.

KW - antigen presentation

KW - cytokines

KW - gene therapy

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029803117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029803117&partnerID=8YFLogxK

M3 - Article

C2 - 9034596

AN - SCOPUS:0029803117

VL - 15

SP - 351

EP - 364

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 3

ER -